The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Systemic lupus erythematosus patients are at risk of ... lupus is seen in approximately 5% of their offspring, whereas congenital heart block is seen in approximately 2%. Repeated fetal ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and ...

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.